Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|June 28, 2012
[Assessing adverse reactions in clinical trials]S Harnisch, C Schade-Brittinger, W RiefClinical Oral Investigations|June 1, 1997
In vivo study on the effectiveness of a lacquer containing CaF2/NaF in treating dentine hypersensitivityA M Kielbassa, T Attin, E Hellwig, et al.Cardiovascular and Interventional Radiology|September 1, 1995
Postmortem evaluation of four randomly selected automated biopsy devices for transthoracic lung biopsyH J Wagner, P Barth, C Schade-Brittinger, et al.The American Journal of Gastroenterology|May 11, 1999
Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumorsM Frank, K J Klose, M Wied, et al.Radiology|March 1, 1994
Renal artery stenosis: grading with image-directed Doppler US evaluation of renal resistive indexW B Schwerk, I K Restrepo, M Stellwaag, et al.European Heart Journal|May 1, 1995
Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine heartsH H Klein, S Pich, S Lindert-Heimberg, et al.Journal of Molecular and Cellular Cardiology|May 29, 1998
Time-dependent protection by Na+/H+ exchange inhibition in a regionally ischemic, reperfused porcine heart preparation with low residual blood flowH H Klein, R M Bohle, S Pich, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2006
Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancerU Seifart, T Fink, C Schade-Brittinger, et al.Basic Research in Cardiology|May 1, 1993
Postischemic cell death in reperfused porcine hearts is not attenuated by the spin trap agent PBN during early reperfusionH H Klein, A Stier, S Pich, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and backgroundP Harter, A du Bois, C Schade-Brittinger, et al.Pageof 2